Multiple GEO datasets from the TIDE website further validated poor prognosis in patients with high CTU2 mRNA levels in BRCA, COAD, DLBC, LUAD, SARC, and melanoma (Figure 3B). This evidence concerns the gene CTU2 and melanoma.